Skip to main content
. 2023 Feb 11;58(4):313–345. doi: 10.1007/s00535-023-01958-z

Fig. 1.

Fig. 1

Initial assessment and choice of therapy in patients with active fistulizing perianal disease. CRP C-reactive protein, CT computed tomography, EUA examination under anesthesia, IM immunomodulator, MRI magnetic resonance imaging, TNF tumor necrosis factor